Prosecution Insights
Prosecution Insights
9 pending office actions • 7 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (67%) |
| No statute on record | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAO, BIN | 1 | 100.0% | +0.0% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.4% |
| SZNAIDMAN, MARCOS L | 1 | 36.9% | +15.9% |
| MCMILLIAN, KARA RENITA | 1 | 30.6% | +37.9% |
| JARRELL, NOBLE E | 1 | 81.3% | +9.0% |
| HIBSHMAN, SARAH GRACE | 1 | 40.9% | +46.3% |
| SCHMIDT, IZABELA MARIA | 1 | 63.1% | +53.5% |
| CHENG, KAREN | 1 | 76.3% | +28.1% |
| BEANE, RANDALL L | 1 | 32.5% | +37.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799774 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | JARRELL, NOBLE E | 8d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17434389 | ALBUMIN-BOUND COMPOSITION INCLUDING LRRD2 OF SLIT3 PROTEIN FOR PREVENTION OR TREATMENT OF BONE-RELATED DISEASES | BEANE, RANDALL L | 112d overdue |
| 17610303 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | CHENG, KAREN | 79d overdue |
| 18562428 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN | VALENROD, YEVGENY | 25d overdue |
| 17772855 | Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same | SCHMIDT, IZABELA MARIA | 5d overdue |
| 17774888 | Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine | HIBSHMAN, SARAH GRACE | 5d |
| 18022982 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | MCMILLIAN, KARA RENITA | 12d |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | SZNAIDMAN, MARCOS L | 26d |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1623 | 2 |
| 1625 | 1 |
| 1699 | 1 |
| 1693 | 1 |
| 1621 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | TAO, BIN | 1625 | Other | Non-Final OA | 21d | Pending | Jan 05, 2024 |
| 18562428 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN | VALENROD, YEVGENY | 1628 | §103 | Non-Final OA | 25d overdue | Pending | Nov 20, 2023 |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | SZNAIDMAN, MARCOS L | 1628 | Other | Non-Final OA | 26d | Pending | Nov 15, 2023 |
| 18022982 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | MCMILLIAN, KARA RENITA | 1623 | §103 | Final Rejection | 12d | Pending | Feb 23, 2023 |
| 17799774 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | JARRELL, NOBLE E | 1699 | §103 | Non-Final OA | 8d | Pending | Aug 15, 2022 |
| 17774888 | Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine | HIBSHMAN, SARAH GRACE | 1693 | Other | Final Rejection | 5d | Pending | May 06, 2022 |
| 17772855 | Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same | SCHMIDT, IZABELA MARIA | 1621 | §103 | Non-Final OA | 5d overdue | Pending | Apr 28, 2022 |
| 17610303 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | CHENG, KAREN | 1623 | §103 | Non-Final OA | 79d overdue | Pending | Nov 10, 2021 |
| 17434389 | ALBUMIN-BOUND COMPOSITION INCLUDING LRRD2 OF SLIT3 PROTEIN FOR PREVENTION OR TREATMENT OF BONE-RELATED DISEASES | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 112d overdue | Pending | Aug 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial